Abstract
Animals treated with a sufficiently high dose of busulphan die about 14 days later from bone marrow failure. A single, appropriately timed injection of cyclophosphamide can save these mice. The nature of this protection is shown to be the cyclophosphamide induced elaboration of a humoral factor which stimulates haemopoietic recovery.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Millar, J., Hudspith, B. & Blackett, N. Reduced lethality in mice receiving a combined dose of cyclophosphamide and busulphan. Br J Cancer 32, 193–198 (1975). https://doi.org/10.1038/bjc.1975.149
Issue Date:
DOI: https://doi.org/10.1038/bjc.1975.149
- Springer Nature Limited
This article is cited by
-
The effect of administration order of BU and CY on engraftment and toxicity in HSCT mouse model
Bone Marrow Transplantation (2008)
-
Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations
British Journal of Cancer (1999)
-
The effect of treatment with high dose melphalan, cisplatin or carboplatin on levels of glutathione in plasma, erythrocytes, mononuclear cells and urine
Cancer Chemotherapy and Pharmacology (1996)
-
Influence of scheduling on two-drug combinations of alkylating agents in vivo
Cancer Chemotherapy and Pharmacology (1989)
-
Radioprotection by pretreatment with deuterated water: cytokinetic changes in the small intestine of the mouse
Virchows Archiv B Cell Pathology Including Molecular Pathology (1987)